Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | APP | P05067 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | VDR | P11473 | 5/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | ALPG | P10696 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14612426 | 0.99 | MAPT (0.51) | MAPTAPPMEN1KMT2AALDH1A1 | |
| SCHEMBL6128371 | 0.99 | MAPT (0.51) | MAPTAPPMEN1KMT2AALDH1A1 | |
| SCHEMBL13236528 | 0.86 | MAPT (0.55) | MAPTAPPMEN1KMT2AALDH1A1 | |
| SCHEMBL15215440 | 0.86 | MAPT (0.49) | MAPTAPPMEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL2323911 | 0.86 | MAPT (0.56) | MAPTAPPMEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL29363133 | 0.86 | MAPT (0.56) | MAPTAPPMEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL2401411 | 0.86 | MAPT (0.56) | MAPTAPPMEN1KMT2AALDH1A1 | |
| SCHEMBL13235947 | 0.85 | VDR (0.46) | MAPTAPPMEN1KMT2AALDH1A1 | |
| SCHEMBL13043718 | 0.84 | MAPT (0.57) | MAPTAPPMEN1KMT2AALDH1A1 | |
| SCHEMBL13043721 | 0.84 | MAPT (0.54) | MAPTAPPMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023164252-A1 | ISOTHERMAL NUCLEIC ACID DETECTION ASSAYS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2026107198-A1 | ANTIBODY BIOMARKER TO DIAGNOSE IDIOPATHIC INFLAMMATORY MYOPATHIES | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20260125675-A1 | DOWNREGULATING TROLLS USING NOVEL ANTISENSE OLIGONUCLEOTIDES TO OVERCOME RESISTANCE TO CHEMOTHERAPY | H LEE MOFFITT CANCER CENTER AND RESEARCH INST INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4731758-A2 | ANTIGEN-SPECIFIC T CELL RECEPTORS AND CHIMERIC ANTIGEN RECEPTORS, AND METHODS OF USE IN IMMUNE SIGNALING MODULATION FOR CANCER IMMUNOTHERAPY | The Methodist Hospital (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12590974-B2 | Methods and compositions for cardiovascular disease detection and management | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4705328-A2 | METHODS AND PLATFORM RELATED TO FLUORESCENT PROTEIN BIOSENSORS | Board of Regents, The University of Texas System (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260062756-A1 | DIAGNOSTIC TO SUPPORT CLINICAL TRIAL MATCHING AND EXPLORATORY BIOMARKER ANALYSES IN CANCER PATIENTS | H LEE MOFFITT CANCER CT & RES (US) | 2026-03-05 | — | — | US | disclosed |
| US-12565680-B2 | Cancer neoantigens and their utilities in cancer vaccines and TCR-based cancer immunotherapy | THE METHODIST HOSPITAL SYSTEM (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260043086-A1 | PREDICTIVE BIOMARKER IN AVASTIN IN COLON CANCER | H LEE MOFFITT CANCER CT & RES (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4689667-A1 | METHODS OF IDENTIFYING IMMUNOGLOBULIN ASSOCIATED WITH ADVERSE REACTIONS | CSL Behring AG (CH) | 2026-02-11 | — | — | EP | disclosed |
| US-11312949-B2 | Engineered heme-binding compositions and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3980451-A1 | ARTIFICIAL RECEPTORS, RECOMBINANT CELLS COMPRISING THEREOF, METHODS FOR THEIR PREPARATION, AND METHOD OF USING THEREOF | Yeda Research and Development Co. Ltd (IL) | 2022-04-13 | — | — | EP | disclosed |
| US-11287427-B2 | Application of anti-CD39L3 antibodies for use in disease diagnostics and imaging | VANDERBILT UNIVERSITY (US) | 2022-03-29 | — | — | US | disclosed |
| US-11274306-B2 | Method for inhibiting calcification of a smooth muscle cell (SMC) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220064697-A1 | AMPLIFICATION METHODS AND SYSTEMS FOR MERFISH AND OTHER APPLICATIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-03-03 | — | — | US | disclosed |
| US-20220064459-A1 | INK COMPOSITION AND METHOD FOR PRODUCING INK COMPOSITION | SEIKO EPSON CORPORATION (JP) | 2022-03-03 | — | — | US | disclosed |
| US-11254786-B2 | Multifunctional degradable nanoparticles with control over size and functionalities | VANDERBILT UNIVERSITY (US) | 2022-02-22 | — | — | US | disclosed |
| WO-2022032129-A1 | SINGLE-CELL LOCUS-SPECIFIC PROFILING OF EPIGENETIC MARKS | YALE UNIVERSITY (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2021263211-A9 | ANTIGEN-SPECIFIC T CELL RECEPTORS AND CHIMERIC ANTIGEN RECEPTORS, AND METHODS OF USE IN IMMUNE SIGNALING MODULATION FOR CANCER IMMUNOTHERAPY | Houston Methodist Hospital (US) | 2022-02-03 | — | — | WO | disclosed |
| US-11236149-B2 | Microbe-binding molecules and uses thereof | PRESIDENT AND FALLOWS OF HARVARD COLLEGE (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254786-B2 | Multifunctional degradable nanoparticles with control over size and functionalities | DSTN, PARN, CTSA | MAPT 1922/4885APP 1006/4885MEN1 1242/4885 |
| US-12590974-B2 | Methods and compositions for cardiovascular disease detection and management | TNNT2, SPTBN1, ATP2A2 | MAPT 1246/4885APP 268/4885MEN1 2546/4885 |
| US-12565680-B2 | Cancer neoantigens and their utilities in cancer vaccines and TCR-based cancer immunotherapy | KDM2A, KDM1A, KDM3A | MAPT 1531/4885APP 526/4885MEN1 3376/4885 |
| US-11312949-B2 | Engineered heme-binding compositions and uses thereof | MB, MYOF, HMBS | MAPT 2841/4885APP 2677/4885MEN1 4583/4885 |
| US-20260125675-A1 | DOWNREGULATING TROLLS USING NOVEL ANTISENSE OLIGONUCLEOTIDES TO OVERCOME RESISTANCE TO CHEMOTHERAPY | PDCD1LG2, TRMT1L, TTLL12 | MAPT 1637/4885APP 4219/4885MEN1 3567/4885 |
| US-20260062756-A1 | DIAGNOSTIC TO SUPPORT CLINICAL TRIAL MATCHING AND EXPLORATORY BIOMARKER ANALYSES IN CANCER PATIENTS | CDK12, CHEK1, AURKB | MAPT 3960/4885APP 3476/4885MEN1 1530/4885 |
| US-20260043086-A1 | PREDICTIVE BIOMARKER IN AVASTIN IN COLON CANCER | WEE2, PARP2, FLT4 | MAPT 4590/4885APP 4521/4885MEN1 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.